Literature DB >> 8471741

Influence of atherosclerosis on the vascular reactivity of isolated human epicardial coronary arteries to leukotriene C4.

S P Allen1, M R Dashwood, A H Chester, S Tadjkarimi, M Collins, P J Piper, M H Yacoub.   

Abstract

Leukotrienes, lipid mediators derived from arachidonic acid by the 5-lipoxygenase pathway, have been implicated in a variety of myocardial ischemic events including myocardial infarction and coronary spasm. We have examined the comparative effects of leukotriene C4 in isolated human non-atherosclerotic and atherosclerotic coronary arteries to gain an insight into the role of leukotrienes in coronary heart disease. Human coronary arteries, obtained from recipient hearts at the time of cardiac transplantation, were cut into rings and examined in an isolated organ bath. In atherosclerotic arteries leukotriene C4 (1nM-100nM) produced a maximal contractile response of 54.9 +/- 7.98% KCI (n = 7) and the mean EC50 value was 11.1nM (95% confidence interval: 9.4-13.0). The leukotriene receptor antagonist ICI-198,615 (3 x 10(-8)M) produced an approximate 50-fold rightward shift of the leukotriene C4 dose-response curve (n = 5). In contrast, non-atherosclerotic arteries were either non-responsive (n = 5) or only weakly responsive (n = 2) to leukotriene C4 (1nM-100nM), producing an average maximum response of 3.65 +/- 3.05% KCI (n = 7; p < 0.01 atherosclerotic vs non-atherosclerotic). In the presence of indomethacin and in vessels denuded of endothelium, non-atherosclerotic arteries remained unresponsive to leukotriene C4 (n = 3). In addition, leukotriene C4 did not relax preconstricted vessels (n = 7). In vitro autoradiography showed specific [3H]-leukotriene C4 binding to smooth muscle in both non-atherosclerotic and atherosclerotic arteries, with no evidence of endothelium-dependent binding.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8471741

Source DB:  PubMed          Journal:  Cardioscience        ISSN: 1015-5007


  3 in total

1.  Pharmacological characterization of the first potent and selective antagonist at the cysteinyl leukotriene 2 (CysLT(2)) receptor.

Authors:  F Wunder; H Tinel; R Kast; A Geerts; E M Becker; P Kolkhof; J Hütter; J Ergüden; M Härter
Journal:  Br J Pharmacol       Date:  2010-05       Impact factor: 8.739

2.  Cysteinyl leukotriene signaling through perinuclear CysLT(1) receptors on vascular smooth muscle cells transduces nuclear calcium signaling and alterations of gene expression.

Authors:  Alison Eaton; Edit Nagy; Mathilde Pacault; Jérémy Fauconnier; Magnus Bäck
Journal:  J Mol Med (Berl)       Date:  2012-04-20       Impact factor: 4.599

Review 3.  Role of the Cysteinyl Leukotrienes in the Pathogenesis and Progression of Cardiovascular Diseases.

Authors:  Francesca Colazzo; Paolo Gelosa; Elena Tremoli; Luigi Sironi; Laura Castiglioni
Journal:  Mediators Inflamm       Date:  2017-08-28       Impact factor: 4.711

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.